MetaCap

Replimune Group Quarterly Income Statement

NASDAQ: REPLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

19.07-0.16 (-0.83%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Replimune Group revenue and earnings

Replimune Group reported a net loss of $57.1 million, compared with a loss of $83.1 million a year earlier. Diluted earnings per share came in at -$0.54.

Summary generated from market data by MetaCap's automated system. Methodology

Replimune Group income statement (quarterly)

Replimune Group quarterly income statement
Quarter (USD)Q2 20272026-09-30Q1 20272026-06-30Q4 20262026-03-31Q3 20262025-12-31Q2 20262025-09-30Q1 20262025-06-30Q4 20252025-03-31Q3 20252024-12-31Q2 20252024-09-30Q1 20252024-06-30Q4 20242024-03-31Q3 20242023-12-31
Operating Expenses56.28M68.25M73.34M71.87M84.29M90.42M79.33M66.02M58.92M57.37M58.76M56.54M
Research & Development34.37M49.28M52.32M53.14M57.88M57.84M53.98M48.00M43.45M42.97M42.58M42.85M
Selling, General & Admin21.92M18.97M——26.41M32.58M——————
Operating Income-56.28M-68.25M-73.34M-71.87M-84.29M-90.42M-79.33M-66.02M-58.92M-57.37M-58.76M-56.54M
Interest Expense2.52M2.58M2.37M1.47M1.49M1.48M1.46M1.45M1.44M1.43M1.41M1.01M
Other Income (Expense)-840.00K-1.52M-119.00K627.00K1.19M3.73M5.09M254.00K5.86M3.60M3.62M5.89M
Pretax Income——-73.46M-71.24M——-74.24M-65.77M-53.05M-53.77M-55.14M-50.65M
Income Tax——-240.00K-311.00K00-107.00K575.00K00-65.00K473.00K
Net Income-57.12M-69.77M-73.22M-70.93M-83.10M-86.69M-74.13M-66.34M-53.05M-53.77M-55.08M-51.12M
Net Income growth (YoY)————————————
EPS (Basic)-0.54-0.72-0.76-0.77-0.90-0.95-0.82-0.79-0.68-0.78-0.82-0.77
EPS (Diluted)-0.54-0.72-0.76-0.77-0.90-0.95-0.82-0.79-0.68-0.78-0.82-0.77
Shares Outstanding (Basic)105.18M96.86M—92.19M91.92M91.52M—83.50M78.57M69.19M—66.65M
Shares Outstanding (Diluted)105.18M96.86M—92.19M91.92M91.52M—83.50M78.57M69.19M—66.65M
EBITDA-55.48M-67.31M-72.57M-71.07M-83.49M-89.55M-78.48M-65.02M-58.02M-56.63M-58.05M-55.84M

This table shows 12 quarterly periods of Replimune Group's income statement, from Q2 2027 back to Q3 2024, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow REPL's reporting calendar. What is a income statement?

More financial data